On January 3, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the "Acceptance Notification" for the listing application of Maribavir Tablets issued by the National Medical Products Administration.
Maribavir is an antiviral drug that targets human CMV, used for the treatment of cytomegalovirus (CMV) infection and/or disease after hematopoietic stem cell transplantation or solid organ transplantation, and is indicated for adult patients with resistance to one or more prior treatments (such as Ganciclovir, Valganciclovir, Sidofovir, or Foscarnet), with or without genotype resistance.
